The FDA has revised Bristol-Myers Squibb’s breakthrough therapy designation for its daclatasvir/sofosbuvir combination hepatitis C therapy to cover patients with advanced cirrhosis or whose infection recurs after a liver transplant. [Read more…]
A new, experimental diabetes drug from AstraZeneca and Bristol-Myers Squibb called dapagliflozin, a Type 2 diabetes treatment developed showed some positive results, according to a presentation at the American Diabetes Association annual conference.
The companies reported that "no discontinuations due to adverse events and no serious adverse events" occurred. Furthermore, pre-clinical data also revealed that in tests on diabetic rats, the treatment significantly reduced plasma glucose levels–in some cases only two hours after a first dose.